Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer

Phase 1

Completed

• Conditions: Carcinoma, Non-small-cell Lung

• Registration Number: NCT00047801
• Lead Sponsor: Telik

Brief Summary

The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-10
• Study First Submitted: 2002-10-18
• Study First Submitted QC: 2002-10-18
• Study First Posted: 2002-10-21
• Primary Completion: 2004-09
• Study Completion: 2004-09
• Status Verified: 2011-06
• Last Update Submitted: 2011-07-21
• Last Update Posted: 2011-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (4)

M.D. Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

UCLA Medical Center; 🇺🇸 Los Angeles, California, United States

Cancer Institute Medical Group; 🇺🇸 Los Angeles, California, United States

Indiana University Cancer Center; 🇺🇸 Indianapolis, Indiana, United States